Balancing the Hopes and Risks of Ketamine Treatment for Major Depressive Episodes

Off

Featuring:

Gerard Sanacora, MD, PhD
and
Professional
Tuesday, March 28, 2017 12:00 pm
Level
Introductory
Category
Depression

There is mounting interest in the use of ketamine and other novel drugs that may produce a rapid onset of antidepressant effects in mood and other neuropsychiatric disorders.  This presentation will highlight the rationale for this approach, critically review the emerging data from several clinical trials, and discus the limitations of the studies completed to date.   In specific we will review the available data on the efficacy and safety of ketamine and other putative rapidly acting antidepressants in the context of mechanism of action, practical clinical usefulness, and its ability to inform future drug development and patient care. 

At the end of this session, participants will be able to:

  1. Describe the current unmet needs for novel antidepressant treatment approaches
  2. Critically evaluate current data from clinical trials on rapidly acting antidepressant mediations and discuss putative mechanisms of action related to rapid onset antidepressant drugs
  3. Summarize the issues associated with the rapidly rising use of ketamine in clinical settings

Presentation level: Introductory

*Please note that this webinar is not eligible for continuing education credit.

Presenter(s) Biography

Gerard Sanacora, MD, PhD

gerard

Dr. Sanacora is currently a Professor of Psychiatry and the Director of the Yale Depression Research Program. He completed an NIH sponsored Medical Scientist Training Program at the State University New York at Stony Brook, earning his Ph.D. in Physiology and Biophysics in 1992 and his M.D. degree in 1994. Dr. Sanacora then moved to Yale University where he completed his internship at Yale-New Haven Hospital, the Clinical Neuroscientist Training Program Residency in the Department of Psychiatry, and an NIH funded Neuroimaging Scientist Training Program Fellowship. Dr. Sanacora’s work is concentrated largely on elucidating the pathophysiological mechanisms associated with mood and other neuropsychiatric disorders. Much of his recent research has focused on identifying the contributions of the amino acid neurotransmitter systems (GABA and Glutamate) to the neurobiology of mood disorders and the mechanism of antidepressant action. In addition, he is involved in several early phase clinical trials designed to test the clinical efficacy of newly developed therapeutic agents.

 

     

and
Professional Post
Off
CE/CME Accreditation Statement

ADAA Continuing Education Credits for Live and On-Demand Programming

Learners complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available.  If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Some ADAA professional webinars focused on diversity or cultural competency subject matter are eligible for the Cross-Culture Competency Diversity Credit. If a webinar is eligible for this credit, it will be reflected on your credit certificate.

All continuing education credits are provided through Amedco, LLC. Learn more about the CE/CME accreditation information here.